Patents by Inventor Kristen Mulvihill

Kristen Mulvihill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-substituted benzimidazolyl c-Kit inhibitors
    Patent number: 7521448
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.
    Type: Grant
    Filed: August 16, 2004
    Date of Patent: April 21, 2009
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Joshua Bolger, Arlindo L. Castelhano, Andrew Phillip Crew, Han-Qing Dong, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Mulvihill, Li Qiu, Colin Peter Sambrook Smith, Yingchaun Sun, Graham Michael Wynne, Tao Zhang
  • Process to prepare substituted imidazopyrazine compounds
    Publication number: 20070129547
    Abstract: A method of preparing wherein, X=Cl, Br, I, comprises the step of treating with N-chloro-, N-bromo-, or N-iodosuccinimide in a compatible solvent such as dimethylformamide (DMF) at 0-60° C. followed by halogenation.
    Type: Application
    Filed: December 7, 2006
    Publication date: June 7, 2007
    Inventors: Kristen Mulvihill, Arlindo Castelhano
  • Fused bicyclic mTOR inhibitors
    Publication number: 20070112005
    Abstract: Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.
    Type: Application
    Filed: November 15, 2006
    Publication date: May 17, 2007
    Inventors: Xin Chen, Heather Coate, Andrew Crew, Han-Qing Dong, Ayako Honda, Mark Mulvihill, Paula Tavares, Jing Wang, Douglas Werner, Kristen Mulvihill, Kam Siu, Bijoy Panicker, Apoorba Bharadwaj, Lee Arnold, Meizhong Jin, Brian Volk, Qinghua Weng, James Beard
  • 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors
    Publication number: 20060235031
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Application
    Filed: March 31, 2005
    Publication date: October 19, 2006
    Inventors: Lee Arnold, Heather Coate, Andrew Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Mulvihill, Mark Mulvihill, Anthony Nigro, Bijoy Panicker, Arno Steinig, Qingua Weng, Douglas Werner, Michael Wyle, Tao Zhang, Cara Cesario, Yingchuan Sun
  • N-substituted benzimidazolyl c-Kit inhibitors
    Publication number: 20060189629
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.
    Type: Application
    Filed: August 16, 2004
    Publication date: August 24, 2006
    Inventors: Joshua Bolger, Arlindo Castelhano, Andrew Crew, Han-Qing Dong, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Mulvihill, Li Qiu, Colin Sambrook Smith, Yingchaun Sun, Graham Wynne, Tao Zhang